Loading Ticker...
You Are Here: Home » Pharma

GSK To Acquire Human Genome Sciences For Rs. 1.39 Lakh Crores?

After its takeover was rejected last month by the U.S. biotech group’s board, the GlaxoSmithKline will take its $2.6 billion bid for Human Genome Sciences direct to stakeholders. According to Hodson Stonex, currently the sixth largest investor in Human Genome, GSK made a good decision.

GSK Logo Glaxo SmithKline

GSK - Glaxo SmithKline

But, still they will be facing payments for this. The fate of the company does not rely on their decision, but on the decision of the investors who share about 78 percent of the shares.

The company together with other US-base company is in pursuit in creating a drug that is for diabetes and heart diseases. These medicines are expected to be a good seller for the company.

HGS India Logo Human Genome Sciences

HGS India - Human Genome Sciences

We all know that there are a lot of people these days who are suffering from diabetes and heart ailments. This goes to show that the product they made is quite timely. Human Genome sciences will surely be a good asset for GSK that is why they are offering to as much as $2.6 bn (Approx. Rs. 1,39,231 Crores) in order to acquire it.


Share this post

Subscribe to our updates via e-mail or get our  RSS Feed
Enter your email address:

Other Related Stories: